Botaretigene sparoparvovec

N/A

Report date: 2026/04/20 20:01:59

Base Information

Drug NameBotaretigene sparoparvovec
Drug Alias NameAAV5-hRKp.RPGR眼内注射溶液AAV-RPGR - MeiraGTxAAV5-hRKp.RPGRAAV2/5-hRKp.RPGR - MeiraGTxAAV5-RPGR +[9] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV5 vector
Mechanisms of ActionRPGR gene transference
TargetsX-linked retinitis pigmentosa GTPase regulator
Therapy Area/IndicationsRetinitis Pigmentosa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMeiragtx Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson (China) Investment LtdMeiragtx Holdings PlcMeiragtx Uk Ii Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsRetinitis Pigmentosa
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A